A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types

ClinicalTrials.gov ID: NCT04300556

Public ClinicalTrials.gov record NCT04300556. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced May 17, 2026, 5:10 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multicenter, Open-Label Phase 1/2 Trial Evaluating the Safety, Tolerability, and Efficacy of MORAb-202, a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Subjects With Selected Tumor Types

Study identification

NCT ID: NCT04300556
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 1, Phase 2
Lead sponsor: Eisai Inc.; Industry
Enrollment: 182 participants

Conditions and interventions

Conditions

Solid Tumor

Interventions

Dexamethasone Drug
Farletuzumab ecteribulin Drug
Lenvatinib Drug
Prednisolone Drug
Prednisone Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Aug 5, 2020
Primary completion: Aug 7, 2030
Completion: Aug 7, 2030
Last update posted: Mar 12, 2026

2020 – 2030

United States locations

U.S. sites: 24
U.S. states: 17
U.S. cities: 22

Facility	City	State	ZIP	Site status
ACRC/Arizona Clinical Research Center, Inc	Tucson	Arizona	85715	Withdrawn
Universty of Arkansas for Medical Sciences	Little Rock	Arkansas	72205	Completed
Stanford Women's Cancer Center	Palo Alto	California	94304	Recruiting
University of Miami	Coral Gables	Florida	33146	Completed
Moffitt Cancer Center and Research Institute	Tampa	Florida	33612	Recruiting
Winship Cancer Institute	Atlanta	Georgia	30322	Completed
Georgia Cancer Center	Augusta	Georgia	30912	Recruiting
Northwestern Memorial Hospital	Chicago	Illinois	60611	Recruiting
Ascension Illinois-Skokie Infustion Center	Skokie	Illinois	60077	Withdrawn
Norton Healthcare	Louisville	Kentucky	40202	Withdrawn
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	Baltimore	Maryland	21287	Completed
Karmanos Cancer Institute	Detroit	Michigan	48201	Completed
Henry Ford Hospital	Detroit	Michigan	48202	Withdrawn
MD Anderson Cancer Center at Cooper	Camden	New Jersey	08103	Completed
Columbia University Medical Center	New York	New York	10032	Completed
Memorial Sloan Kettering Cancer Center	New York	New York	10065	Recruiting
University of Cincinnati Medical Center	Cincinnati	Ohio	45219	Completed
OSU Wxner Medical Center	Hilliard	Ohio	43026	Withdrawn
Oregon Health & Science University	Portland	Oregon	97239	Withdrawn
Medical University of South Carolina	Charleston	South Carolina	29425	Withdrawn
Chattanooga's Program in Women's Oncology	Chattanooga	Tennessee	37403	Completed
Vanderbilt University Medical Center	Nashville	Tennessee	07677	Withdrawn
The University of Texas MD Anderson Cancer Center	Houston	Texas	77030	Withdrawn
University of Virginia Comprehensive Cancer Center	Charlottesville	Virginia	22903	Completed

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 34 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT04300556, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Mar 12, 2026 · Synced May 17, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04300556 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →